Details of the Drug Combination

General Information of Drug Combination (ID: DCCD82J)

Drug Combination Name

Indazole derivative 5 Terameprocol

Indication

Disease Entry	Status	REF
High grade ovarian serous adenocarcinoma	Investigative	[1]

Component Drugs

Indazole derivative 5 DMM1I8R

Terameprocol DMC3P45

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: OVCAR-5

Zero Interaction Potency (ZIP) Score: 2.74

Bliss Independence Score: 4.56

Loewe Additivity Score: 3.09

LHighest Single Agent (HSA) Score: 3.11

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Clear cell renal cell carcinoma	DCV87W6	786-0	Investigative	[4]
Plasma cell myeloma	DCSUAG1	RPMI-8226	Investigative	[4]
Renal cell carcinoma	DCQNXMZ	UO-31	Investigative	[4]
Carcinoma	DC12K85	RXF 393	Investigative	[5]
Colon adenocarcinoma	DCUX42S	COLO 205	Investigative	[5]
Invasive ductal carcinoma	DC5OXWP	T-47D	Investigative	[5]
Invasive ductal carcinoma	DC217OB	BT-549	Investigative	[5]
Adenocarcinoma	DC9SH51	DU-145	Investigative	[1]
Adenocarcinoma	DCIMZ2J	NCIH23	Investigative	[1]
Adenocarcinoma	DCVQ2K0	HT29	Investigative	[1]
Cutaneous melanoma	DC0RCV4	SK-MEL-28	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCPFLPO	NCI\\/ADR-RES	Investigative	[1]
Lung adenocarcinoma	DCRJ3J5	HOP-62	Investigative	[1]
Melanoma	DCRTPNL	SK-MEL-2	Investigative	[1]
Melanoma	DCR8L8L	MALME-3M	Investigative	[1]
Non-small cell lung carcinoma	DCRHAR1	HOP-92	Investigative	[1]
Ovarian serous cystadenocarcinoma	DCWZWBU	SK-OV-3	Investigative	[1]
Pleural epithelioid mesothelioma	DCIHAEI	NCI-H226	Investigative	[1]
Prostate carcinoma	DCZHKYJ	PC-3	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 19 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3	Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
5	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165